Business Description
TEYI PHARMACEUTICAL GROUP CO LTD
ISIN : CNE100001WK6
Share Class Description:
SZSE:002728: Class ACompare
Compare
Traded in other countries / regions
002728.China IPO Date
2014-07-31Description
TEYI PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company. It engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical drugs and raw materials in China. The main pharmaceutical preparation products cover a cough and phlegm, kidney, anti-infection, cardiovascular and digestive system. The main preparation products include Zhikebao Tablet, Jinqi Shenqi Tablet, Pharyngitis Tablet, and Erythromycin Enteric-coated Tablets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.98 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 1.55 | |||||
| Interest Coverage | 14.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 7.57 | |||||
| Beneish M-Score | -2.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.7 | |||||
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 84.1 | |||||
| 3-Year FCF Growth Rate | 6.1 | |||||
| 3-Year Book Growth Rate | 13.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.7 | |||||
| 9-Day RSI | 27.79 | |||||
| 14-Day RSI | 32.89 | |||||
| 6-1 Month Momentum % | -11.1 | |||||
| 12-1 Month Momentum % | -5.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 1.84 | |||||
| Cash Ratio | 1.42 | |||||
| Days Inventory | 217.96 | |||||
| Days Sales Outstanding | 30.92 | |||||
| Days Payable | 67.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.24 | |||||
| Dividend Payout Ratio | 1.31 | |||||
| 3-Year Dividend Growth Rate | 6.6 | |||||
| Forward Dividend Yield % | 5.24 | |||||
| 5-Year Yield-on-Cost % | 7.88 | |||||
| 3-Year Average Share Buyback Ratio | -8.6 | |||||
| Shareholder Yield % | 14.24 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.85 | |||||
| Operating Margin % | 20.75 | |||||
| Net Margin % | 16.91 | |||||
| FCF Margin % | 4.49 | |||||
| ROE % | 9.05 | |||||
| ROA % | 6.49 | |||||
| ROIC % | 8.68 | |||||
| ROC (Joel Greenblatt) % | 21.4 | |||||
| ROCE % | 10.8 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 28.18 | |||||
| PE Ratio without NRI | 26.26 | |||||
| Shiller PE Ratio | 27.81 | |||||
| Price-to-Owner-Earnings | 63.49 | |||||
| PEG Ratio | 9.38 | |||||
| PS Ratio | 4.68 | |||||
| PB Ratio | 2.34 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| Price-to-Free-Cash-Flow | 149.52 | |||||
| Price-to-Operating-Cash-Flow | 35.79 | |||||
| EV-to-EBIT | 24.03 | |||||
| EV-to-EBITDA | 24.03 | |||||
| EV-to-Revenue | 4.94 | |||||
| EV-to-FCF | 110.17 | |||||
| Price-to-Projected-FCF | 1.51 | |||||
| Price-to-Graham-Number | 2.06 | |||||
| Price-to-Net-Current-Asset-Value | 7.88 | |||||
| Price-to-Net-Cash | 34.74 | |||||
| Earnings Yield (Greenblatt) % | 4.16 | |||||
| FCF Yield % | 0.88 | |||||
| Forward Rate of Return (Yacktman) % | 4.9 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TEYI PHARMACEUTICAL GROUP CO LTD Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 927.667 | ||
| EPS (TTM) (Â¥) | 0.329 | ||
| Beta | 3.94 | ||
| Volatility % | 50.73 | ||
| 14-Day RSI | 32.89 | ||
| 14-Day ATR (Â¥) | 0.47292 | ||
| 20-Day SMA (Â¥) | 10.772857 | ||
| 12-1 Month Momentum % | -5.63 | ||
| 52-Week Range (Â¥) | 8.25 - 17.485714 | ||
| Shares Outstanding (Mil) | 510.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TEYI PHARMACEUTICAL GROUP CO LTD Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TEYI PHARMACEUTICAL GROUP CO LTD Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
TEYI PHARMACEUTICAL GROUP CO LTD Frequently Asked Questions
What is TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728)'s stock price today?
The current price of SZSE:002728 is ¥9.38. The 52 week high of SZSE:002728 is ¥17.49 and 52 week low is ¥8.25.
When is next earnings date of TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728)?
The next earnings date of TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728) is .
Does TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728) pay dividends? If so, how much?
The Dividend Yield %  of TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728) is 5.24% (As of Today), Highest Dividend Payout Ratio of TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728) was 4.4. The lowest was 0.14. And the median was 0.83. The  Forward Dividend Yield % of TEYI PHARMACEUTICAL GROUP CO LTD(SZSE:002728) is 5.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers